Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study

被引:9
作者
Rovati, LC [1 ]
Setnikar, I [1 ]
Genazzani, AR [1 ]
机构
[1] Rotta Res Lab SpA, Dept Clin Pharmacol, I-20052 Monza, Italy
关键词
transdermal estradiol; hormone replacement therapy (HRT); randomized controlled clinical trial; matrix patch;
D O I
10.3109/09513590009167695
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New estradiol (E-2) transdermal matrix patches developed for once-a-week application, releasing 25 mu g E-2 (7D-25) or 50 mu g E-2 (7D-50) daily, were investigated in comparison with a placebo patch and the twice-weekly parent patch releasing 50 mu g E-2 (Derm-50) daily. Three hundred and eleven postmenopausal patients suffering at least seven hot flushes daily were randomly assigned to the four parallel groups and treated continuously for 12 weeks without progestin opposition. The daily number of hot flushes significantly decreased in all groups. At the 12th week the decrease from a baseline average of eight to nine episodes per day was 78% with 7D-25, 93% and 97% respectively with 7D-50 and Derm-50, and significantly (p < 0.001) lower with placebo (59%). Comparable efficacy was observed in terms of severity of hot flushes, Kupperman Index and patient self-rated overall efficacy. Minor systemic adverse events occurred in 10.0%, 8.8%, 16.9% and 13.5% patients in the placebo, 7d-25, 7D-50 and Derm-50 groups respectively Occasional mild and transient itching and/or erythema at the site of application was reported by a few patients, with no difference between groups or between once-weekly or twice-weekly application. In conclusion all E-2 patches were significantly more effective than placebo in relieving climacteric symptoms in a dose-dependent fashion and all were well tolerated.
引用
收藏
页码:282 / 291
页数:10
相关论文
共 39 条
[1]   CARDIOVASCULAR MORTALITY AND NONCONTRACEPTIVE USE OF ESTROGEN IN WOMEN - RESULTS FROM THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY [J].
BUSH, TL ;
BARRETTCONNOR, E ;
COWAN, LD ;
CRIQUI, MH ;
WALLACE, RB ;
SUCHINDRAN, CM ;
TYROLER, HA ;
RIFKIND, BM .
CIRCULATION, 1987, 75 (06) :1102-1109
[2]   Mortality after all major types of osteoporotic fracture in men and women: an observational study [J].
Center, JR ;
Nguyen, TV ;
Schneider, D ;
Sambrook, PN ;
Eisman, JA .
LANCET, 1999, 353 (9156) :878-882
[3]  
Christiansen C, 1990, Osteoporos Int, V1, P7
[4]  
CHRISTIANSEN C, 1981, LANCET, V1, P459
[5]   MENOPAUSE AND THE RISK OF CORONARY HEART-DISEASE IN WOMEN [J].
COLDITZ, GA ;
WILLETT, WC ;
STAMPFER, MJ ;
ROSNER, B ;
SPEIZER, FE ;
HENNEKENS, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (18) :1105-1110
[6]  
CORFMAN P, 1995, MENOPAUSE, V2, P131
[7]   Endogenous hormones and the risk of hip and vertebral fractures among older women [J].
Cummings, SR ;
Browner, WS ;
Bauer, D ;
Stone, K ;
Ensrud, K ;
Jamal, S ;
Ettinger, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (11) :733-738
[8]  
De Aloysio D, 2000, ARZNEIMITTELFORSCH, V50, pE293
[9]  
Delmas P D, 1997, Osteoporos Int, V7 Suppl 1, pS3
[10]   MENOPAUSAL ESTROGEN REPLACEMENT THERAPY AND BREAST-CANCER [J].
DUPONT, WD ;
PAGE, DL .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :67-72